Clobazam in Adult Drug-Resistant Epilepsy: Excellent Long-Term Retention and Potential Synergy with Neuromodulation

Area of Science:

• Neurology
• Pharmacology

Background:

• Drug-resistant epilepsy (DRE) presents a significant clinical challenge.
• Clobazam, a 1,5-benzodiazepine, is an effective adjunctive therapy for DRE.
• Concerns about clobazam tolerability and discontinuation exist in some studies.

Purpose of the Study:

• To evaluate the long-term efficacy and tolerability of clobazam in adults with DRE.
• To assess outcomes in patients who successfully tolerated clobazam for at least six months.
• To investigate the role of clobazam in combination with neuromodulation devices.

Main Methods:

• Retrospective chart review of 160 adult DRE patients treated with clobazam for ≥6 months.
• Analysis of seizure frequency, clobazam dosage, and tolerability.
• Inclusion of data on concomitant therapies, including neuromodulation devices.

Main Results:

• Significant seizure reduction observed at a mean clobazam dosage of 20 mg/day.
• 62% of patients achieved seizure freedom or near-freedom (≤1 seizure/year).
• Excellent long-term retention (95%) with only 5% discontinuing due to adverse effects among tolerant patients.
• Concomitant clobazam and neuromodulation (VNS/RNS) showed additional seizure reduction.

Conclusions:

• Clobazam demonstrates excellent long-term retention (95%) and sustained efficacy in treatment-tolerant adult DRE patients.
• Combination therapy with clobazam and neuromodulation devices shows potential complementarity.
• Careful ongoing management optimizes clinical outcomes in adult DRE.